PHOENIX — Dupilumab significantly improved swallowing ability and reduced eosinophils in the esophagus, indicating histologic remission, compared with placebo, according to results from the phase 3 LIBERTY-EoE-TREET study.
These results were presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.
“Eosinophilic esophagitis (EoE) is a chronic, progressive type 2 inflammatory disease that damages the esophagus and prevents it from working properly,” Evan S. Dellon, MD, MPH, professor in the department of medicine, division of gastroenterology and